Table 1 Baseline characteristics for entire cohort and for patients who reached and did not reach end-points
All | Died | ESKD | CVE | Any | Test | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 830 | No (n = 226) | Yes (n = 604) | p | No (n = 658) | Yes (n = 172) | p | No (n = 520) | Yes (n = 310) | p | No (n = 148) | Yes (n = 682) | p | ||
Median age (years) | 71.0 (64.8–76.7) | 68.6 | 72.1 | <0.0001 | 71.5 | 70.2 | 0.1 | 71.4 | 70.4 | 0.1 | 69.1 | 71.4 | 0.01 | MWU |
Male (%) | 59.9 | 59.3 | 60.1 | 0.8 | 59 | 63.4 | 0.3 | 58.1 | 62.9 | 0.2 | 57.4 | 60.4 | 0.5 | X 2 |
RAS >70% unilateral (%) | 39.5 | 35.0 | 41.2 | 0.1 | 38.8 | 42.4 | 0.4 | 41.5 | 36.1 | 0.1 | 35.1 | 40.5 | 0.2 | X 2 |
RAS >70% Bilateral (%) | 10.6 | 9.3 | 11.1 | 0.5 | 10.3 | 11.6 | 0.6 | 10.6 | 10.6 | 0.9 | 6.8 | 11.4 | 0.09 | X 2 |
Median patency score | 105.0 (70.0–150.0) | 120.0 | 100.0 | 0.007 | 110.0 | 100.0 | 0.1 | 105.0 | 107.5 | 0.9 | 130.0 | 100.0 | <0.0001 | MWU |
Median SBP mmHg | 152.0 (135.0–175.3) | 152.0 | 152.0 | 0.8 | 154.0 | 150.0 | 0.2 | 150.0 | 153.5 | 0.6 | 150.0 | 152.5 | 0.6 | MWU |
Median DBP mmHg | 80.0 (70.0–90.0) | 79.0 | 80.0 | 0.3 | 80.0 | 80.0 | 0.9 | 80.0 | 80.0 | 0.9 | 79.0 | 80.0 | 0.2 | MWU |
Median MAP mmHg | 103.3 (93.3–115.3) | 101.8 | 103.3 | 0.5 | 103.3 | 101.4 | 0.5 | 102.8 | 103.3 | 0.8 | 100.7 | 103.3 | 0.3 | MWU |
MVD (%) | 71.8 | 63.3 | 75.0 | 0.001 | 71.7 | 72.1 | 0.9 | 68.5 | 77.4 | 0.006 | 60.1 | 74.3 | <0.0001 | X 2 |
CHF (%) | 19.4 | 11.1 | 22.5 | <0.0001 | 19.0 | 20.9 | 0.6 | 17.3 | 22.9 | 0.05 | 8.1 | 21.8 | <0.0001 | X 2 |
FPE (%) | 6.4 | 4.4 | 7.1 | 0.2 | 6.2 | 7.0 | 0.7 | 5.6 | 7.7 | 0.2 | 4.1 | 6.9 | 0.2 | X 2 |
Diabetes (%) | 31.3 | 28.3 | 32.5 | 0.2 | 30.5 | 34.3 | 0.3 | 30.2 | 33.2 | 0.4 | 29.1 | 31.8 | 0.5 | X 2 |
RAB (%) | 50.0 | 66.4 | 43.9 | <0.0001 | 52.1 | 41.9 | 0.02 | 49.6 | 50.6 | 0.8 | 64.9 | 46.8 | <0.0001 | X 2 |
BB (%) | 37.1 | 43.4 | 34.8 | 0.02 | 35.9 | 41.9 | 0.1 | 37.5 | 36.5 | 0.8 | 44.6 | 35.5 | 0.04 | X 2 |
CaB (%) | 55.4 | 52.7 | 56.5 | 0.3 | 52.7 | 65.7 | 0.002 | 54.4 | 57.1 | 0.5 | 48.6 | 56.9 | 0.07 | X 2 |
>3 anti-hypertensives (%) | 48.1 | 54.9 | 45.5 | 0.02 | 47.6 | 50.0 | 0.6 | 45.8 | 51.9 | 0.09 | 53.4 | 46.9 | 0.2 | X 2 |
Aspirin (%) | 54.5 | 54.9 | 54.3 | 0.9 | 54.0 | 56.4 | 0.6 | 50.6 | 61.0 | 0.004 | 52.0 | 55.0 | 0.5 | X 2 |
Statin (%) | 55.9 | 69.9 | 50.7 | <0.0001 | 56.1 | 55.2 | 0.8 | 54.8 | 57.7 | 0.4 | 68.2 | 53.2 | 0.001 | X 2 |
Median Proteinuria (g/day) | 0.6 (0.2–1.2) | 0.3 | 0.6 | <0.0001 | 0.4 | 1.0 | <0.0001 | 0.5 | 0.6 | 0.2 | 0.2 | 0.6 | <0.0001 | MWU |
Median eGFRa (ml/min/1.73 m2) | 29.9 (19.3–43.2) | 36.8 | 27.3 | <0.0001 | 33.4 | 17.4 | <0.0001 | 29.5 | 30.8 | 0.3 | 37.6 | 28.0 | <0.0001 | MWU |
Revascularized (%) | 17.5 | 19.9 | 16.6 | 0.3 | 16.9 | 19.8 | 0.4 | 14.8 | 21.9 | 0.009 | 13.5 | 18.3 | 0.2 | X 2 |